


Human Intelligence Enhanced by Artificial Intelligence

A REVOLUTION IN CARDIOVASCULAR IDENTIFICATION AND MANAGEMENT


CardioCare

Digital Health Platform

The CardioCare platform identifies at-risk patients with atrial fibrillation who could benefit from guideline-directed medical therapy.



30% OF ELIGIBLE AF PATIENTS WERE NOT PRESCRIBED ANTICOAGULATION^{1,2}



1. Analysis from egnite's database of sites participating in the CardioCare platform representing 247,526 AF patients from 20 institutions (both teaching and non-teaching included) as of December 1, 2022. Analysis included patients with an elevated CHA₂DS₂-VASc score (≥ 2 for men and ≥ 3 for women), who are considered potentially eligible for oral anticoagulation per the 2019 AHA/ACC/HRS guidelines for AF. Anticoagulant therapy decisions should include shared decision making and assessment of relative or absolute contraindications/comorbidities for each patient.

2. Patients included in this analysis all received an initial recorded diagnosis of AF associated with a hospitalization or an emergency room visit. Patients were considered to have been prescribed anticoagulation if anticoagulation was prescribed prior to or within 30 days of that initial recorded diagnosis. Patients were categorized as not prescribed anticoagulation if there was no record of an anticoagulation prescription, or an anticoagulation prescription was issued greater than 365 days after initial diagnosis.

atrial fibrillation (AF), guideline-directed medical therapy (GDMT)

DELIVERING ON-DEMAND INSIGHTS OF YOUR AF PATIENT POPULATION TO REDUCE VARIABILITY IN CARE & HELP ENSURE GDMT



The CardioCare platform provides insights to help you increase survival for your atrial fibrillation patients.



Automatically identify AF patients who are not receiving anticoagulation.



Guide facility- and MD-level outreach for patient evaluation and follow-up.



Ensure eligible AF patients with multiple hospitalizations receive appropriate GDMT.

For more information, please visit egnitehealth.com/solutions

[@egnitehealth](https://twitter.com/egnitehealth) [in linkedin.com/company/egnite-health/](https://www.linkedin.com/company/egnite-health/)

The CardioCare platform is not intended for use in the diagnosis, cure, mitigation, or prevention of cardiovascular diseases.

©2023 egnite, Inc. All Rights Reserved. egnite, egnite Inc., the spark logo, CardioCare, and the heart logo are trademarks of egnite, Inc or its affiliates. All other trademarks are property of their respective owners.

PP-US-059 v2.0

